Yahoo! Inc. (NASDAQ:YHOO) Volume Spiking Mid-session

Isaac Cain
May 20, 2017

Yahoo! Inc. (NASDAQ:YHOO)'s stock had its "buy" rating reaffirmed by equities researchers at MKM Partners in a note issued to investors on Wednesday. The lowest 12-month price target for the shares is $13.50, which would be decrease of about -28% of its current value.

Additionally on 10/18/16 Needham "Downgrades" Yahoo! Cantor Fitzgerald set a $50.00 price objective on shares of Yahoo! and gave the stock a "buy" rating in a report on Tuesday, December 20th. About 621,411 shares traded. (NASDAQ:YHOO) last posted its quarterly earnings data on Tuesday, April 18th.

The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) is a huge mover today! Retail Properties of America Inc (NYSE:RPAI) has risen 6.00% since April 19, 2017 and is uptrending. It has by 0.00% the S&P500.The move comes after 5 months negative chart setup for the $2.49 billion company. The 1-year high was reported on May, 19 by Barchart.com. We have $47.24 PT which if reached, will make NASDAQ:AGIO worth $149.40 million less.

Among 5 analysts covering Sohu.com Inc. Inc. had 105 analyst reports since July 22, 2015 according to SRatingsIntel. Analysts have a mean recommendation of 2.40 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Therefore 48% are positive.

02/02/2017 - Yahoo! Inc. had its "equal weight" rating reiterated by analysts at Morgan Stanley. Citigroup maintained Yahoo! Inc. (NASDAQ:YHOO) on Monday, October 17 with "Buy" rating.

More news: Dem calls for Trump impeachment on House floor

YHOO has been the topic of several recent analyst reports. The company was maintained on Friday, August 14 by Brean Capital. On Wednesday, September 16 the stock rating was maintained by M Partners with "Buy". The firm earned "Outperform" rating on Wednesday, April 20 by Oppenheimer. Investors bought 328 put options on the stock. For YHOO, the company now has $1.33 Billion of cash on the books. Utzschneider Lisa sold 451 shares worth $20,272.

Claar Advisors Llc decreased Charter Communications Inc stake by 18,545 shares to 24,517 valued at $7.06 million in 2016Q4. Sensato Invsts Ltd Liability Corporation owns 118,713 shares. Advance Auto Parts Inc (NYSE:AAP) was reduced too. Its up 0.17, from 0.9 in 2016Q3. 59 funds opened positions while 139 raised stakes. Share performance for the month is now at 5.60%.

01/24/2017 - Yahoo! Inc. had its "hold" rating reiterated by analysts at SunTrust. Financial Architects, New Jersey-based fund reported 970 shares. (NASDAQ:YHOO). Fil holds 0.16% or 1.38 million shares. Savings Bank Of Nova Scotia has 0.03% invested in Yahoo! Inc. (NASDAQ:YHOO) for 16,815 shares. Inc.is 1.21 Billion and the High Revenue Estimate is 1.34 Billion. (NASDAQ:YHOO). Sunbelt Incorporated reported 100,000 shares. Andra Ap invested in 0.06% or 58,900 shares. Meiji Yasuda Life owns 14,240 shares for 0.09% of their portfolio. Parkwood Ltd Llc has 10,285 shares for 0.06% of their portfolio. Victory Mgmt owns 16,512 shares or 0% of their U.S. portfolio. Cleararc Capital invested in 21,335 shares. It dived, as 68 investors sold Yahoo! (NASDAQ:YHOO). Richard Bernstein Advsr holds 60,867 shares or 0.2% of its portfolio. Tarbox Gru Inc accumulated 368 shares. Capital Interest Sarl, a California-based fund reported 162,500 shares. Concannon Wealth Ltd Limited Liability Company has 0.01% invested in Yahoo! Inc. Oxford Asset Management has 0.08% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 40,276 shares. Envestnet Asset Mgmt reported 21 shares. State Of Wisconsin Investment Board reported 878,446 shares stake. More interesting news about Yahoo! Inc. They now have a $62.00 price objective on the digital content provider's stock, up from their prior price objective of $58.00.

Agios Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company. Over the short term, some market observers may have noticed that Hewlett Packard Enterprise Company has a 2.20% short float with 15 days to cover. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes.

Other reports by LeisureTravelAid

Discuss This Article

FOLLOW OUR NEWSPAPER